ABVC BioPharma (ABVC) Proxy Filing summary

Executive summary

• The 2026 annual shareholder meeting will be held virtually on March 9, 2026, to vote on director re-elections, auditor ratification, and an amendment to the equity incentive plan.

• Shareholders of record as of January 26, 2026, are entitled to vote, with one vote per share; a quorum requires 33.3% of shares.

• Proxy voting is encouraged as no voting will occur during the virtual meeting; proxies must be submitted by March 8, 2026.

• The board unanimously recommends voting in favor of all proposals.

Voting matters and shareholder proposals

• Proposal 1: Re-election of 11 director nominees to serve until the next annual meeting.

• Proposal 2: Ratification of Simon & Edward, LLP as independent auditor for fiscal year ending December 31, 2026.

• Proposal 3: One-time increase in the equity incentive plan to 15% of outstanding shares, with a 5% annual evergreen provision thereafter.

• Other business may be transacted as properly brought before the meeting.

Board of directors and corporate governance

• The board consists of 11 directors, with nine non-management and several classified as independent under Nasdaq rules.

• Audit, Compensation, and Corporate Governance/Nominating Committees are composed entirely of independent directors.

• Guidelines for director nominees emphasize ethics, experience, and diversity.

• Board leadership is separated between CEO and Chairman; the board oversees risk management.